SLC5A2 and diabetes mellitus: Evidence from CV outcome trials suggests that specific glucose-lowering agents, such as sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), can reduce the risk of major CV events in individuals with diabetes (Table 1) [76].